The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement.
Variations in the use of antidementia and antipsychotic drugs for nursing home residents with dementia across the United ...
The rate of antipsychotic drug use in nursing homes has remained stubbornly high. Experts are concerned about misuse.
The use of SGLT2 inhibitors vs DDP-4 inhibitors is associated with a reduced risk of developing different types of dementia.
Among the adverse effects reported in the trial, infusion-related reactions were observed in 26.4% of patients in the ...
A new study, however by the universities of Manchester, Nottingham, Edinburgh and Dundee, published in the BMJ, has found that antipsychotic drugs prescribed to dementia patients cause more ... light ...
Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in ...
The findings were particularly pronounced in individuals with dementia, pointing to a possible vascular benefit of higher BP.
In a recent study conducted by researchers from Hong Kong, evidence has emerged suggesting that your cholesterol medication ...
However, the National Institute for Health and Care Excellence (Nice) rejected it for use on the NHS saying its benefits are ...
SGLT2 inhibitors and dulaglutide are associated with comparable risk for dementia; however, it is uncertain whether these findings generalize to newer GLP-1 RAs.